Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?

Ann H. Klopp,a Anshul Gupta,a Erika Spaeth,b Michael Andreeff,b Frank Marini, IIIb

aDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; bDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Key Words. Mesenchymal stem cells • Adipose stem cells • Cancer • Stroma • Microenvironment

ABSTRACT

The discovery that mesenchymal stem cells (MSCs) are recruited into tumors has led to a great deal of interest over the past decade in the function of MSCs in tumors. To address this, investigators have used a variety of tumor models in which MSCs are added exogenously to determine their impact on tumor development. Interestingly, many studies have reported contradicting results, with some investigators finding that MSCs promote tumor growth and others reporting that MSCs inhibit tumor growth. Many mechanisms have been reported to account for these observations, such as chemokine signaling, modulation of apoptosis, vascular support, and immune modulation. In this review, we analyzed the differences in the methodology of the studies reported and found that the timing of MSC introduction into tumors may be a critical element. Understanding the conditions in which MSCs enhance tumor growth and metastasis is crucial, both to safely develop MSCs as a therapeutic tool and to advance our understanding of the role of tumor stroma in carcinogenesis.

Disclosure of potential conflicts of interest is found at the end of this article.

INTRODUCTION

Mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs) are multipotent progenitor cells that exhibit a marked tropism for tumors. MSCs form a tumor’s fibrovascular network, differentiating into tumor-associated fibroblasts (TAFs) and vascular pericytes [1–3]. Despite extensive investigations over the past 5 years, the impact of unmodified MSCs on tumor progression remains unclear. Many studies have shown that MSCs promote tumor progression and metastasis while other studies report that MSCs suppress tumor growth (referenced in Tables 1 and 2). The reason for this discrepancy is unknown, but it may be attributable to differences in tumor models, the heterogeneity of MSCs, the dose or timing of the MSCs injected, the animal host, or another factor that is not yet appreciated.

The tropism of MSC for tumors makes MSCs uniquely destined to function as cellular delivery vehicles for antitumor agents [27–32]. MSCs can deliver a diverse array of agents, including interferon (IFN)-β, cytosine deaminase, tumor necrosis factor-related apoptosis-inducing ligand, and oncolytic viruses. These approaches have been explored in preclinical cancer models and yielded potent antitumor effects [29–35]. Tumor-targeted production of antitumor agents is likely to overcome any endogenous tumor-promoting effects of MSCs. However, it is important to determine under what conditions MSCs enhance tumor growth and metastasis to develop therapeutic applications and to understand the role of stroma in tumorigenesis. This review article focuses on studies that directly investigated the effects of MSCs on tumors in vivo and attempts to shed light on the contradictions reported in the literature.

Isolation of MSCs

MSCs have been isolated from many types of adult and fetal tissues using similar methodologies [36]. Bone marrow and adipose tissues are rich sources of MSCs [37, 38]. MSCs have also been isolated from many other adult tissues, including kidney, skin, and the parathyroid gland [38–40]. MSCs or MSC-like cells have also been isolated from fetal tissues, including the skin, umbilical cord, and placenta [33, 41–43]. These tissue-derived MSCs share a number of important characteristics with bone marrow-derived MSCs, including cell surface marker expression, plastic adherence, and the capacity to differentiate into cells of mesenchymal lineage (i.e., fat, bone, muscle, and cartilage) under appropriate conditions [37]. In addition, MSCs demonstrate a tumor tropism that distinguishes them from other mesenchymal cells, such as differentiated fibroblasts [31, 44]. However, tissue-derived MSCs are likely to differ in critical ways from the well-studied bone marrow-derived MSCs. It is possible that the contradictions in study findings are attributable to the variability in MSCs from different sources (i.e., bone marrow-derived MSCs vs. tissue-derived MSCs) and variability in MSCs from donor to donor even when obtained from the same source using the same technique.
MSCs also have complex immunomodulatory effects. MSCs can counteract inflammation, by suppressing host immune responses and preventing fibrosis. The immunosuppressive properties of MSCs are being exploited in an effort to reduce the toxicity of allogeneic bone marrow transplant due to graft versus host disease (GVHD) in which the transplanted cells formulate an immune response against the transplant recipient [48, 49].

Impact of MSC on In Vivo Tumors

MSC Promotion of Tumor Growth

Studies reporting that MSCs can promote tumor growth are listed in Table 1. Karnoub et al. [4] coinjected bone marrow-derived human MSCs with green fluorescent protein-labeled human breast cancer cells (MCF/Ras, MDA-MB-231, MDA-MB-435, and HMLER) in a ratio of 3:1 into immunocompromised mice. The MSCs accelerated tumor growth in one of the four cell lines (MCF/Ras) but did not affect local tumor growth in the other cell types. Coinjection with MSCs increased the number of breast cancer metastases that formed in all cell lines investigated.

Bone marrow-derived MSCs have been shown to increase the in vivo growth of colon cancer, lymphoma, and melanoma cells [5, 6, 50]. Adult- and fetal-derived MSCs were coinjected with colon cancer cells (SW480 and F6) in a murine xenograft model [5], resulting in an increased incidence of tumors with enhanced vascularity and necrosis. Both adult and fetal MSCs had similar growth-promoting effects, but adult MSCs appeared to favor tumor incidence more than fetal MSCs.

B16 melanoma cells transplanted into allogeneic mice did not form tumors unless MSCs were coinjected [6]. This finding suggests MSCs have immunosuppressive effects, which were required for tumor initiation in this model. MSCs also support the in vitro survival of follicular lymphoma B cells derived from human tumors. This protective effect of MSCs was augmented further by treating MSCs with tumor necrosis factor-α and lymphotoxin-2/1β [50].

Adipose tissue is a rich source of multipotent MSCs (referred to as adipose stem cells [ASCs]), which exhibit tumor tropism and are thought to be functionally similar to bone marrow-derived MSCs [40]. Muehlberg et al. [8] demonstrated that ASCs can promote tumor growth in a syngeneic mouse model. Mammary breast cancer cells were cotransplanted with ASCs, resulting in the development of larger and more aggressive tumors than when ASCs were coinjected with colon cancer cells [5]. Muehlberg et al. [8] also demonstrated that MSCs can promote tumor growth in a syngeneic mouse model. Mammary breast cancer cells were cotransplanted with ASCs, resulting in the development of larger and more aggressive tumors than when ASCs were coinjected with colon cancer cells [5].

Endogenous Functions of MSCs

MSCs are thought to endogenously support wound healing and hematopoiesis, but many of the native functions of MSCs remain poorly understood. When engrafted at sites of tissue injury, MSCs differentiate into connective tissue elements, support vasculogenesis, and secrete cytokines and growth factors that facilitate healing. The potential of MSCs to promote tissue repair is being investigated in a diverse array of diseases, including ischemic heart disease, diabetes, and Parkinson’s disease [45].

The function of MSCs in tumors is likely to parallel the role of MSCs in wound healing. As in wounds, MSCs differentiate in tumors into fibroblasts and pericytes and, perhaps, endothelial-like or vessel-attached cells [3, 46]. Additionally, MSCs secrete a number matrix proteins and cytokines that can increase proliferation and support vasculogenesis, such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) [47].

MSCs also have complex immunomodulatory effects. MSCs can counteract inflammation, by suppressing host immune responses and preventing fibrosis. The immunosuppressive properties of MSCs are being exploited in an effort to reduce the toxicity of allogeneic bone marrow transplant due to graft versus host disease (GvHD) in which the transplanted cells formulate an immune response against the transplant recipient [48, 49].

### Table 1. Studies reporting that MSC promote tumor growth

| Author | Isolation | Tumor model | MSC:Tumor cell ratio | Findings | Proposed mechanism |
|--------|-----------|-------------|---------------------|----------|--------------------|
| Karnoub et al. [4] | Human BMD-MSC | Breast (MCF/Ras, MDA-MB-231, MDA-MB-435, and HMLER) | 3:1 co-injected | Increased size in one cell line (MCF/Ras) and increased metastasis | Chemokine secretion (CCL5) |
| Zhu et al. [5] | Fetal and adult BMD-MSCs | Colon cancer cell line (SW480 and F6) | 10:1, 1:1 co-injected | Increased incidence | Enhanced proliferation and angiogenesis |
| Djouad et al. [6, 7] | Mouse BMD-MSC | Melanoma (B16) | 1:1 co-injected | Increased incidence | Immunologic |
| Muehlberg et al. [8] | Human and mouse ASCs | Breast (4T1 and MDA231) | 10:1 co-injected or i.v. 24 hours later | Increased size | Paracrine factor (SDF-1/CXCR4 secretion) |
| Yu et al. [9] | Human ASC | Lung or glioma (H460 or U87MG) | 1:1, 2:1, 1:10 co-injected | Increased size | Reduced apoptosis |
| Galie et al. [10] | Mouse ASC | Breast (BB1) | 1:1 | Increased incidence and size | Vasculogenic |
| Lin et al. [11] | Human ASC | Prostate (PC3) | 1:2 injected in contralateral flank after 7 days | Increased incidence and size | Vasculogenic and modulation of tumoral CXCR4 |
| Kucerova et al. [12] | Human ASC | Melanoma (A375 and M4Beu) and glioblastoma multiforme (8MGBA) | 1:10-1:5 co-injected or i.v. synchronous with tumor injections | Decreased latency and increased size of melanoma xenografts | VEGF and SDF-1α/CXCR4 |
| Pranit et al. [13] | Human ASC | Prostate | 1:10 coinjection subcutaneously | Increased size | Vasculogenic with differentiation into endothelial cells |
| Shinagawa et al. [14] | Human MSC | Colon (KM12SM) | 1:2 Coinjected into cecum | Increased size and metastasis | Increased angiogenesis and reduced apoptosis |

**Abbreviations:** ASC, adipose stem cell; BMD, bone-marrow derived; CCL5, chemokine ligand 5; CXCR4, C-X-C chemokine receptor type 4; i.v., intravenous delivery; MSC, mesenchymal stem cell; SDF, stromal-derived factor; VEGF, vascular endothelial growth factor.
Table 2. Studies reporting that mesenchymal stem cells inhibit tumor growth

| Author                  | Isolation          | Tumor model                          | MSC:tumor cell ratio          | Findings                        | Proposed mechanism                        |
|-------------------------|--------------------|--------------------------------------|--------------------------------|----------------------------------|-------------------------------------------|
| Ohlsson et al. [15]     | MPC1cE MSC         | Rat colon carcinoma cells (H1D1)     | 1:1 and 10:1 in gelatin matrix | Tumor size smaller               | Increased inflammatory infiltrate          |
| Khakoo et al. [16]      | Human BMD-MSC      | Kaposi sarcoma                       | 3 x 10^6 MSC injected i.v.    | Tumor size smaller               | AKT signaling                             |
| Qiao et al. [17]        | Human fetal skin   | Human hepatoma cell line (H7402 HepG2)| 1:1 coinjection              | Tumor size smaller               | Wnt signaling                             |
| Qiao et al. [18]        | Human fetal skin   | Breast cell line (MCF-7)             | 1:100 coinjection             | Increased latency, reduced tumor size, and metastasis | Wnt signaling                             |
| Zhu et al. [19]         | Human ASC          | Human myelogenous leukemia (K562) cell line in nude mice | 1:10 grown isolation in vivo | Proliferation inhibited          | Secretion of DKK-1                        |
| Otsu et al. [20]        | Rat BMD-MSC        | Mouse B16F10 melanoma cell line      | 10^6 into a established 700 mm3 tumor | Tumor size smaller               | Inhibition of angiogenesis                |
| Cousin et al. [21]      | Human ASC          | Pancreatic cancer cells              | 10^3 ASCs per mm3 of established tumor | Tumor size smaller               | G1 arrest                                  |
| Maestroni et al. [22]   | BMD-MSC            | Lewis lung and melanoma (B16)        | 1:1 coinjected                | Tumor size smaller and decreased metastasis | Increased by treatment of MSC with GM-CSF |
| Lu et al. [23]          | Mouse BMD-MSC      | Hepatoma (H22), lymphoma (Tac-1 and EL-4), and rat insulinoma (INS-1) | 2:4:1 i.p. into tumor-bearing mice | Decreased ascites formation | Induced apoptosis and cell cycle arrest in G0/G1 phase |
| Dasari et al. [24, 25]  | Umbilical cord blood-derived | Gliona (SNB19 and U251, 4910 and 5310) | 1:4 injected 7 days later into contralateral hemisphere | Decreased tumor size | Upregulation of PTEN                        |
| Secchiero et al [26]    | BMD-MSC            | Non-Hodgkins lymphoma (SKW6.4 and BJAB) | 1:10 and 1:2 injected i.p. 4 days later | Decreased tumor burden with increased survival | Endothelial cell apoptosis in vitro |

Abbreviations: ASC, adipose stem cell; BMD, bone-marrow-derived; DKK1, Dickkopf-related protein-1; GM-CSF, granulocyte-macrophage colony-stimulating factor; i.p., intraperitoneally; i.v., intravenously; MSC, mesenchymal stem cell; PTEN, phosphatase and tensin homolog.
may have been a consequence of the immunogenicity of the MSCs transplanted into a nonidentical rat strain and may have contributed to the antitumor effect of MSCs in this model. In a highly inflammatory and angiogenic Kaposis sarcoma model, MSCs but not human umbilical vein endothelial cells, inhibited tumor growth in the xenografts [16]. The use of athymic nude mice in these experiments suggests that the inhibitory effects of MSCs were not due to immunomodulatory effects.

Human fetal skin-derived MSCs inhibited human liver cancer cell lines, with reduced proliferation, colony formation, and oncogene expression both in vitro and in vivo [17]. When these cell lines were co injected with the same number of MSCs, tumor development was delayed and tumor size decreased.

The same fetal skin-derived MSCs inhibited growth of MCF-7 breast cancer cells in vitro [18]. The researchers found that treatment with conditioned media resulted in downregulation of survival factors, such as β-catenin, c-Myc, and survivin. This effect was mediated by an inhibitor of β-catenin signaling, Dickkopf-related protein-1 (DKK-1), which is secreted by MSCs [18]. The DKK-1 effects were suppressed in MSCs with the use of a neutralizing antibody and small interfering RNA, eliminating the growth inhibitory effects of MSCs.

Adipose-derived MSCs were also found to inhibit proliferation of primary leukemia cells [19]. This effect was mediated by secreted DKK-1, which was regulated by the stem cell transcription factor NANOG [19].

MSCs have been shown to suppress pancreatic tumors by altering cell cycle progression. In vitro coculture with MSCs increased rates of G1-phase arrest in pancreatic cancer cells [21]. In vivo injection of adipose-derived stem cells into established pancreatic cancer xenografts inhibited tumor growth [21]. In a similar approach, bone marrow-derived MSCs were injected into established subcutaneous melanomas, resulting in apoptosis and abrogation of tumor growth [20]. When MSCs were placed in a Matrigel insert, such that tumors were exposed to soluble factors but not in contact with MSC, MSCs had no cytotoxic effects.

The impact of hyperthermic treatment was tested in an in vitro study in which adipose-derived stem cells were heated [57]. Ovarian cancer SKOV-3 cells were cultured with supernatant from these heat-treated MSCs, resulting in decreased cell number and viability. Cho et al. [57] proposed that the decrease in cell number and viability was due to various secreted factors, including angiogenin, insulin-like growth factor (IGF) binding protein 4, neurotrophin 3, and chemokine (C–C motif) ligand (CCL) 18 [57].

**Mechanisms of MSC-Mediated Effects of Tumor Support or Suppression**

**Vascular Support**

MSCs have been reported to support the tumor vasculature directly, by differentiating into pericytes and perhaps endothelial cells [58] and through indirect mechanisms, by secreting vasculogenic growth factors [59]. Two lines of evidence suggest that MSCs differentiated into pericytes. Transplanted MSCs engraft in the perivascular niche in close contact with the underlying endothelial cells [60]. In addition, pericytes isolated from the stromal-vascular compartment have been shown to contain a MSC-like population with characteristic cell surface marker expression (CD10, CD13, and CD90) and the capacity to differentiate into tissues of mesenchymal lineage [61, 62]. Within mouse brain, a population of MSC-like cells has been identified in the perivascular area [63].

MSCs also secrete various proangiogenic factors, such as VEGF, fibroblast-derived growth factor, PDGF, and stromal-derived factor-1 (SDF-1). These cytokines promote endothelial and smooth muscle migration and proliferation at the tumor site, facilitating angiogenesis [64, 65].

MSC-secreted factors, such as VEGF, support blood vessel growth. MSCs expressing VEGF increased microvessel density in pancreatic xenografts [47]. However, recombinant VEGF at the same concentration found in the MSC-conditioned media did not have the same proliferative effect on vessel growth as did the MSC-conditioned media [65], suggesting that other proangiogenic cytokines are also involved. Other growth factors implicated in MSC effects on tumor vasculature include hepatocyte growth factor, cyclooxygenase, IGF-1, PDGF-α, and transforming growth factor-β1 [47]. Interestingly, expression of proangiogenic factors is increased by growth of MSCs as spheroids as compared with growth as monolayers [64].

In what appears to be a direct conflict with this data, MSCs appear to inhibit capillary growth under certain conditions. MSCs migrate in vitro toward endothelial cell-derived capillaries in Matrigel, incorporate into these vessels, and produce reactive oxygen species, resulting in endothelial cell apoptosis [20]. These researchers found that an endothelial cell to MSC ratio of 1:1 or 1:3 resulted in cytotoxicity but coinjection with 10% MSC resulted in no cytotoxicity. The growth-suppressing effect of MSCs was observed in vivo in which established melanomas injected with MSCs had reduced tumor growth and tumors exhibited lower vascular density [20].

**Fibrovascular Network**

Fibroblasts, which are the primary cell type comprising tumor stroma, are a critical component of the tumor microenvironment. Tumor fibroblasts (referred to as TAFs) are derived in part from MSCs that may be recruited regionally or from circulating populations [44, 66]. After exposure to the tumor microenvironment, MSCs acquire expression of TAF antigens, such as α-smooth muscle actin, fibroblast-specific protein, vimentin, and SDF-1 in vivo and in vitro following coculture with tumor cells or using tumor-conditioned media [3, 66].

The importance of TAFs in promoting tumorigenesis has been well established in multiple tumor models [67]. TAFs extracted from human tumors facilitate the growth of human breast and ovarian cancers when co.injected into immunosuppressed mice [68]. This appears to involve multiple mechanisms, including the inhibition of cancer cell apoptosis, increased tumor cell proliferation, and promotion of angiogenesis. Thus, the acquisition of a TAF phenotype in MSC-derived tumor stroma provides indirect evidence for the protumor effect of MSCs.

**Immunomodulatory Effects of MSCs in Tumors**

MSCs are generally thought to have immunosuppressive effects, which may be an important mechanism through which MSCs promote tumor growth or increase incidence of tumor formation in vivo. MSCs can directly impair the function of a variety of immune cells, including B and T lymphocytes, dendritic cells, and natural killer cells [69–75]. These immunosuppressive qualities of MSCs have been exploited to reduce GvHD following allogeneic stem cell transplantation [76, 77]. MSCs suppress T-cell proliferation through multiple mechanisms. IFN-γ directly enhances the T-cell suppressive effects of MSCs through upregulation of an inhibitory cell surface marker, B7-H1 [78]. A subpopulation of MSC, identified by Stry-1+ expression, has the most potently inhibitory effects on T-cell proliferation [79].
Toll-like receptor (TLR) signaling has recently been shown to regulate the immunomodulatory properties of MSCs [80]. TLR respond to “danger” signals triggering the innate and adaptive immune responses. MSC express TLR and activation of certain receptors can polarize MSC to switch from a predominately immune suppressive to a proinflammatory phenotype [80]. It is possible that discrepant reports in the literature may be attributed to the activation of different TLR as a consequence of variability in TLR expression and environmental ligand expression.

The immunomodulatory effects of MSCs, if any, are not well understood within tumors. Djouad et al. [6] reported that the immunosuppressive action of MSCs led to a higher incidence of melanoma formation in a mouse model. Evidence for the effect of MSCs on tumor immunology also comes from a clinical study conducted to investigate whether the immunosuppressive effects of MSCs could reduce the immunologic side effects of GVHD. Cotransplantation of MSCs has been reported to reduce the incidence of GVHD, but delivery of MSCs was also associated with higher rates of leukemia relapse in one study [77]. These results suggest that MSCs may have suppressed the graft versus leukemia effect and the graft versus host response. Alternatively, MSCs may have directly supported leukemia progression through other mechanisms, for example, by generating a specialized bone marrow niche supportive of residual leukemic cells [81, 82]. Clinical studies of the potential immunosuppressive effects of MSCs in Crohn’s disease are in progress.

**Metastasis**

Karnoub et al. reported that MSC-secreted CCL5 induced a transient prometastatic effect on breast cancer cells [4]. Tumors coinjected with MSCs exhibited a twofold increase in the number of breast cancer cells in the lungs [4]. Tumor cells isolated from the lung metastasis had equal rates of metastasis as compared with breast cancer cells taken from the primary tumors, suggesting that the effect of MSCs on metastasis is primarily not due to selection of a population of cells with an increased capacity to metastasize but rather to transient changes elicited by exposure to MSCs. Additionally, the prometastatic effect required the MSCs to be injected together with the tumor cells and was not seen when MSCs were injected distantly, demonstrating that the effect requires contact or exposure to paracrine signaling from the MSCs. Furthermore, MSCs themselves were not found in the pulmonary metastasis. These experiments support a model in which MSC-secreted factors reversibly modify tumor cells to increase their metastatic potential. The researchers additionally found that there was no increase in the number of metastatic tumor cells seen in the murine lungs when tumor cells were coinjected with other cells of mesenchymal lineage, suggesting that the prometastatic effect is a unique quality of MSCs. CCL5 secreted by MSCs and chemokine receptor 5 expression on breast cancer cells was found to be critical for the prometastatic effect of MSCs in two of the four breast cancer cell lines tested [4].

MSCs may modulate the epithelial-to-mesenchymal transition (EMT), a developmental process that is subverted by tumor cells resulting in a more invasive phenotype [83]. In breast cancer, coculture with MSCs resulted in upregulation of EMT-specific markers (N-cadherin, vimentin, Twist, and Snail) and a decrease in E-cadherin [84]. A similar effect was observed in prostate cancer cells that were cocultured with carcinoma-associated fibroblasts [85]. We observed that MSC-secreted factors increase mammosphere formation in normal and malignant breast cells and that mammospheres formed in the presence of MSC-conditioned media exhibited lower levels of E-cadherin expression and an increase in N-cadherin expression, characteristic of EMT [86]. This may be an additional mechanism by which MSCs influence tumor cell metastasis.

MSCs may also modify the metastatic niche, supporting the formation of early metastasis through vasculogenesis or growth factor secretion. For example, Corcoran et al. [87] reported that MSCs facilitated the entry of breast cancer cells into the bone marrow through Tac-1 regulation of SDF-1 and C-X-C chemokine receptor type 4 (CXCR4), a G-protein couple receptor.

**Secretion of Paracrine Factors**

MSCs secrete a variety of growth factors that are known to influence tumor proliferation, migration, and angiogenesis (Table 3). In addition, MSCs have also been recently reported to secrete exosomes or microparticles [94, 95]. Microparticles are lipid vesicles that are less than 1 mm in diameter and are secreted by cells. They may contain proteins or RNA that regulate intracellular signaling in adjacent cells [94, 95]. MSC-secreted microparticles contain microRNAs in the precursor form, which represent a subset of microRNAs found within MSCs. MSC-secreted microparticles may thus be one of the unappreciated mechanisms of MSC signaling within the tumor microenvironment.

**Modulating Tumor Response to Cytotoxic Therapy**

Although a great deal of research has focused on the role of MSCs as delivery vehicles for antitumor proteins or viruses, targeting endogenous MSCs in tumors also has the potential to be an effective therapy. Studies investigating the effects of MSCs on response to cytotoxic therapy have demonstrated that MSCs can protect tumor cells from chemotherapy. Interactions with MSCs in bone marrow has been shown to promote survival of acute and chronic myelogenous leukemia [82, 96–98]. Coculturing MSCs with acute myelogenous leukemia cells resulted in the upregulation of antiapoptotic bcl-2 with reduced rates of apoptosis in response to cytotoxic therapy.
MSCs interact with tumor cells in a myriad of ways, which have the potential to support or suppress tumor growth. Additionally, MSCs interact with their tumor-resident neighbors, such as immune cells (macrophages and T cells) and endothelial cells. Other cell types have also been shown to play roles in modulating tumor progression, thereby potentially exacerbating or inhibiting the outcomes of the MSC-tumor interactions.

The heterogeneity in MSC is likely a major factor contributing to the inconsistent reports about the effects of MSC in tumors. The MSC used in the studies reviewed here were isolated largely on the basis of plastic adherence. These MSCs exhibited appropriate cell surface marker expression as well as multipotency and yet these cell populations are fundamentally different in critical ways. To address this concern, cell surface markers that permit isolation of a more homogenous population are needed. Several markers, such as NG2 [100], have been proposed to be useful makers to identify a more homogenous population of MSC, which could make the results of studies such as these more readily comparable.

The studies reviewed here reported both growth promotion and suppression for the same cell types, including adult- and fetal-derived bone marrow, suggesting that the age of the donor does not determine the effect of MSC on tumor progression. Zhu et al. [5] directly compared the effects of bone marrow-derived MSCs isolated from a 40-week fetus with the effects of bone marrow-derived MSCs isolated from an adult. The researchers found marked growth promotion from both cell types. However, the tumors injected with adult MSCs developed more rapidly (100% incidence of tumors by day 20) than did those injected with fetal MSCs (20%–80% tumor incidence by day 20), suggesting that the adult MSCs had greater tumor growth-promoting activity.

The effects of propagating cells ex vivo are also variable and may contribute to these discrepant results. Authors have reported growing MSC in high serum or growth factor supplemented media, which may alter the MSC phenotype. In addition, passage number and confluence may impact MSC function. Studies using endogenously labeled lineages of stromal cells will eliminate these concerns and will help clarify the effects of MSC or MSC-like cell in vivo. Finally, it is not known what proportion of “MSC” cell lines are contaminated with tumor cells, such as reported contamination with osteosarcoma and glioma cells used in the same laboratories [15]. Fingerprinting of all cell lines used should therefore be rigorous and will help reducing confusion regarding biological properties of MSC.

In vivo tumor models vary widely and may also account for some of the differences in the findings of these studies. Tumor immunity, hypoxia, angiogenesis, and cytokine secretion are all highly variable in the models described in these studies. However, MCF-7 breast cells and B16 melanoma cells were reported by different investigators to be both promoted and suppressed by MSC delivery, suggesting that the tumor model is not the only factor accounting for the disparate findings.

The dose of MSCs delivered has been proposed to be a determinant of MSC effects on tumor growth. In general, studies that reported growth promotion tended to use a higher MSC to tumor cell ratio. However, low percentages of MSCs, such as the 10% used by Yu et al. [9], promoted subcutaneous growth in a lung and glioma cell line. These researchers [49] reported that coinjection of a higher percentage of MSCs further augmented tumor growth, suggesting that, in the right conditions, MSCs may impact tumor growth in a dose-dependent manner.

The timing at which MSCs are introduced into the tumor microenvironment may be an important consideration. All three of the studies that introduced MSCs into established tumors reported tumor growth inhibition [21, 20, 23]. Three other studies reporting growth inhibition involved modifications, such as implantation into a gelatin matrix or intravenous delivery of MSCs, which may have minimized the direct contact of MSCs during tumor initiation. By contrast, all of the studies reporting growth promotion mixed MSCs with tumor cells and coinjected the cells. The presence of MSCs during early tumor growth may facilitate processes, such as angiogenesis, which are required for tumor initiation. This hypothesis is consistent with the studies investigating MSC interactions with the vasculature. Coinjection of MSCs with pancreatic cancer cells resulted in increased vessel density, which required MSC-derived VEGF expression [47]. By contrast, MSCs induced endothelial cell apoptosis in established Matrigel capillaries, and delivery of MSCs into established melanoma xenografts abrogated tumor growth.

Finally, patient-to-patient variability in MSC isolates may also contribute to the conflicting data reported in the literature. It is possible that due to genetic, epigenetic, or environmental effects, MSCs may have different effects on the tumor microenvironment and could conceivably contribute to an individual’s cancer risk. To address this, studies of MSCs from patients predisposed to cancer because of somatic mutations, such as BRCA, or environmental exposures, such as cigarette smoking, may be helpful to determine if patient-to-patient variability exists.

In summary, no simple paradigm can account for the conflicting findings in the studies of MSCs. Understanding the nuances of the interaction between MSCs and cancer cells is especially critical given the therapeutic potential of MSCs. The possibility of MSCs promoting tumor growth and metastasis raises concerns about the safety of their use as clinical tools. No evidence of tumor formation has been reported in over 1,000 patients treated with MSC for a variety of indications, so far. MSCs that have been engineered to express anti-tumor cytokines have potent antitumor effects, suggesting that perhaps putative tumor-promoting effects of MSCs can be overcome by manipulating cytokine expression. Additionally, MSCs could also be engineered to express a suicide gene so that MSCs delivered systemically would migrate into tumors, express an antitumor protein, and then be terminated with the delivery of an agent, such as gancyclovir, resulting in selective termination of the exogenously delivered MSCs. Furthermore, therapeutic strategies aimed at disrupting tumor-promoting effects of MSCs opens the door to a novel therapeutic strategy, but this would need to be properly timed to prevent disruption of a growth-suppressive MSC-tumor cell interaction. This review highlights the critical need for studies designed to explicitly test the hypothesis that tissue source, individual donor variability, timing of MSC injection, or expression of critical receptors such as TLR, determine the
effect of MSC on tumor progression. Only systematic analysis of the role of these and other factors will resolve this important issue.

ACKNOWLEDGMENT

This study was supported by MDACC Institutional core grant (CA016672), NIH (CA116199, CA55164, 1R01 FD003733, R21C, RCICA1463, RCICA146381, CA109451, and CA083639), and the Paul and Mary Haas Chair in Genetics to M.A.

REFERENCES

1 Hata N, Shinohjima N, Gumin J et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 2010;66:144–156; discussion 156–157.

2 Kidd S, Spaeth E, Dembinski JL et al. Direct evidence of mesenchymal stem cell tropism for tumor and woundng microenvironmets using in vivo bioluminescent imaging. Stem Cells 2009;27: 264–2623.

3 Spaeth EL, Dembinski JL, Sasser AK et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. Plos One 2009; 4:e9992.

4 Kamoun AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007:449: 557–563.

5 Zhu W, Xu W, Jiang R et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006; 80:267–274.

6 Djoud F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogenic animals. Blood 2003;102:3837–3844.

7 Djoud F, Bony C, Apparailly F et al. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006;82:1060–1066.

8 Muelhberg F, Song YH, Krohn A et al. Tissue resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009;30:589–597.

9 Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008;17:463–473.

10 Galie M, Konstantinidou G, Peroni D et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene 2008;27: 2542–2551.

11 Lin G, Yang R, Banie L et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010; 70:1066–1073.

12 Kucerova L, Matuskova M, Hlubinova K et al. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010;9:1–15.

13 Prantl L, Muelhberg F, Navone NM et al. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 2010;70: 1709–1715.

14 Shinagawa K, Kitadai Y, Tanaka M et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127:2323–2333.

15 Torsvik A, Rosland GV, Svendsen A et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: Putting the research held on track - letter. Cancer Res 2010;70:6393–6396.

16 Khakoo AY, Patti S, Anderson SA et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 2006;205:1235–1247.

17 Qiao L, Xu Z, Zhao T et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008;18: 500–507.

18 Qiao L, Xu ZL, Zhao TJ et al. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 2008;269:67–77.

19 Zhu Y, Sun Z, Han Q et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009;23: 925–933.

20 Otsu K, Das S, Houser SD et al. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009;113: 4197–4205.

21 Cousin B, Ravet E, Poglio S et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. Plos One 2009;4:e6278.

22 Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 1999;55:663–667.

23 Lu YR, Yuan Y, Wang XJ et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008;7:245–251.

24 Dasari VR, Velpula KK, Kaur K et al. Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One 2010;5:e11813.

25 Seccichio P, Zorzet S, Tripodo C et al. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin’s lymphoma xenografts. PLoS One 2010; 5:e11140.

26 Yong RL, Shinohjima N, Fueyo J et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic ade- novirus Delta24-RGD to human gliomas. Cancer Res 2009;69: 8932–8940.

27 Kidd S, Caldwell L, Dietrich M et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory therapy. Cytotherapy 2010; 12:615–625.

28 Mader EK, Maeyama Y, Lin Y et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009;15: 7246–7255.

29 Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593–1603.

30 Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307–3318.

31 Studeny M, Marini FC, Champlin RE et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603–3608.

32 Kim SM, Lim JY, Park SI et al. Gene therapy using TRAIL-secret- ing human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614–9623.

33 Josiah DT, Zhu D, Dreher F et al. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther 2010;18:377–385.

34 Dwyer RM, Khan S, Barry FP et al. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010;1: 2010–2025.

35 Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of mesenchymal stromal cells: Implications for cell lineage commitment and plasticity of adult stem cells. The International Society For Cellular Therapeutics position statement. Cytotherapy 2006;8: 315–317.

36 For Cellular Therapy position statement. Cytotherapy 2006;8: 315–317.

37 Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society For Cellular Therapy position statement. Cytotherapy 2006;8: 315–317.

38 Pereira TF, Halford KW, O’Hara MD et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartil- age, and lung in irradiated mice. Proc Natl Acad Sci USA 1995;92: 4857–4861.

39 Shih YR, Kuo TK, Yang AH et al. Isolation and characterization of stem cells from the human parathyroid gland. Cell Proli 2009;42: 461–470.
Dubois SG, Floyd EZ, Zvonic S et al. Isolation of human adipose-derived stem cells from biopsies and liposuction specimens. Methods Mol Biol 2008;449:69–79.

Bieback K, Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2007;2:310–323.

Flynn A, Barry F, O’Brien T. UC blood-derived mesenchymal stromal cells: An overview. Cytotherapy 2007;9:717–726.

Gucciardo L, Lories R, Ochsenbein-Kolble N et al. Fetal mesenchymal stem cells: Isolation, properties and potential use in perinatology and regenerative medicine. BJOG 2009;116:166–172.

Sparenth E, Klopp A, Dembinski J, Andreff M, Marinii F. Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15:730–738.

Brooke G, Cook M, Blair C et al. Therapeutic applications of mesenchymal stromal stem cells. Semin Cell Dev Biol 2007;18:846–858.

Short B, Brouard N, Occhiodoro-Scott T et al. Mesenchymal stem cells. Arch Med Res 2003;34:565–571.

Beckermann BM, Kallfatsidus G, Groth A et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 2008;99:622–631.

Wolff D, Steiner B, Hildebrandt G et al. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des 2009;15:3974–3997.

Rajantie I, Ilmonen M, Alminaite A et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for bone marrow stromal cells. Stem Cells Dev 2007;16:1651–1657.

Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035–3039.

Rosland GV, Svensden A, Torsvik A et al. Hyperthermia-treated mesenchymal stem cells express genes encoding a broad spectrum of arteriogenic cytokines. Circ Res 2010;67:711–720.

Zeng Z, Shi YX, Samudio IJ et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2008;113:6215–6224.

Iwatsuki M, Mimori K, Yokobori T et al. Epithelial-mesenchymal transition and cancer stemness. Cancer Res 2009;69:3313–3322.

Cho JA, Park H, Kim HK et al. Hydrometamorphic bone marrow derived cells recruit during angiogenesis define precursors for periendothelial vascular mural cells. Blood 2004;104:2084–2086.

Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301–313.

Traktuev DO, Merfeld-Clauss S, Andreeff M, Marini F. A perivascular origin for mesenchymal stem cells recruited during angiogenesis. Circ Res 2009;105:77–85.
93 Tabe Y, Konopleva M, Munsell MF et al. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 2004;103:1815–1822.

94 Kozanoğlu I, Boga C, Özdogu H et al. Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification. Cytotherapy 2009;11:527–533.

95 Walter MN, Wright KT, Fuller HR et al. Mesenchymal stem cell-conditioned medium accelerates skin wound healing: An in vitro study of fibroblast and keratinocyte scratch assays. Exp Cell Res 2010;316:1271–1281.

96 Seib FP, Prewitz M, Werner C et al. Matrix elasticity regulates the secretory profile of human bone marrow-derived multipotent mesenchymal stromal cells (MSCs). Biochem Biophys Res Commun 2009;389:663–667.

97 Park KS, Kim YS, Kim JH et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation 2010;89:509–517.

98 Liu CH, Hwang SM. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005;32:270–279.

99 Salazar KD, Lankford SM, Brody AR. Mesenchymal stem cells produce Wnt isoforms and TGF-beta1 that mediate proliferation and procollagen expression by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009;297:L1002–L1011.

100 Molloy AP, Martin FT, Dwyer RM et al. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009;124:326–332.